|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 10, 2016 ) The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.
For more information about this report at http://www.reportsweb.com/osteosarcoma-pipeline-review-h2-2016
Report Scope:
- The report provides a snapshot of the global therapeutic landscape of Osteosarcoma
- The report reviews pipeline therapeutics for Osteosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Osteosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Osteosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Osteosarcoma
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001391644/sample
Reasons to buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Osteosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Companies profiles
Advaxis, Inc.
Amgen Inc.
AVEO Pharmaceuticals, Inc.
Bayer AG
Bellicum Pharmaceuticals, Inc.
Celldex Therapeutics, Inc.
CytRx Corporation
Eleison Pharmaceuticals LLC
Exelixis, Inc.
Isofol Medical AB
MediaPharma s.r.l.
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Netris Pharma S.A.S.
Novartis AG
Oncolys BioPharma Inc
Pfizer Inc.
Shionogi & Co., Ltd.
Teijin Pharma Limited
United Therapeutics Corporation
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001391644/discount
List of Figures:
Number of Products under Development for Osteosarcoma, H2 2016 12
Number of Products under Development for Osteosarcoma - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Products, H2 2016 18
Assessment by Monotherapy Products, H2 2016 41
Number of Products by Top 10 Targets, H2 2016 42
Number of Products by Stage and Top 10 Targets, H2 2016 42
Number of Products by Top 10 Mechanism of Actions, H2 2016 45
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 45
Number of Products by Routes of Administration, H2 2016 48
Number of Products by Stage and Routes of Administration, H2 2016 48
Number of Products by Molecule Types, H2 2016 50
Number of Products by Stage and Molecule Types, H2 2016 50
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
